Healx

Healx is an AI-powered techbio company based in Cambridge, United Kingdom, founded in 2014. The company specializes in accelerating drug discovery and development for rare diseases through its proprietary AI platform, Healnet. By combining artificial intelligence with pharmacological expertise, Healx aims to make drug development faster, cheaper, and more successful, targeting to advance 100 treatments toward clinical trials by 2025. The Healnet platform analyzes extensive drug and disease data to identify new connections and repurpose existing drugs. Healx has launched 17 programs across various rare disease areas, including neuro, respiratory, and oncology, with a strong track record of preclinical validation. The company is advancing several therapies through its pipeline, including HLX-1502 for neurofibromatosis type 1 and programs for Fragile X syndrome and other conditions. Healx also collaborates with patient groups and pharmaceutical companies to enhance treatment discovery and development.